A detailed history of Morgan Stanley transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 650,226 shares of SUPN stock, worth $17.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
650,226
Previous 723,355 10.11%
Holding current value
$17.6 Million
Previous $20.9 Million 5.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$27.11 - $35.17 $1.98 Million - $2.57 Million
-73,129 Reduced 10.11%
650,226 $22.2 Million
Q4 2023

Feb 13, 2024

BUY
$22.72 - $29.68 $4.43 Million - $5.78 Million
194,776 Added 36.85%
723,355 $20.9 Million
Q3 2023

Nov 15, 2023

SELL
$27.57 - $32.91 $753,184 - $899,068
-27,319 Reduced 4.91%
528,579 $14.6 Million
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $449,038 - $581,453
15,013 Added 2.78%
555,898 $16.7 Million
Q1 2023

May 15, 2023

SELL
$34.93 - $42.03 $6.62 Million - $7.97 Million
-189,558 Reduced 25.95%
540,885 $19.6 Million
Q4 2022

Feb 14, 2023

BUY
$31.09 - $37.88 $6.68 Million - $8.13 Million
214,709 Added 41.63%
730,443 $26.1 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $1.2 Million - $1.48 Million
41,705 Added 8.8%
515,734 $17.5 Million
Q2 2022

Oct 27, 2022

BUY
$25.33 - $34.25 $6.11 Million - $8.27 Million
241,325 Added 103.7%
474,029 $13.7 Million
Q2 2022

Aug 15, 2022

BUY
$25.33 - $34.25 $6.11 Million - $8.27 Million
241,325 Added 103.7%
474,029 $13.7 Million
Q1 2022

Oct 27, 2022

SELL
$28.51 - $32.9 $6.88 Million - $7.94 Million
-241,325 Reduced 50.91%
232,704 $7.52 Million
Q1 2022

May 13, 2022

SELL
$28.51 - $32.9 $1.29 Million - $1.49 Million
-45,348 Reduced 16.31%
232,704 $7.52 Million
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $1.41 Million - $1.82 Million
53,295 Added 23.71%
278,052 $8.11 Million
Q3 2021

Nov 15, 2021

BUY
$23.54 - $31.39 $5.29 Million - $7.06 Million
224,757 New
224,757 $6 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.45B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.